Jump to Main Content
- Surnar, Bapurao; Kolishetti, Nagesh; Basu, Uttara; Ahmad, Anis; Goka, Erik; Marples, Brian; Kolb, David; Lippman, Marc E.; Dhar, Shanta
- Biochemistry 2018 v.57 no.46 pp. 6500-6513
- DNA; DNA damage; adverse effects; antineoplastic activity; aspirin; cisplatin; drug therapy; in vitro studies; models; nausea; nephrotoxicity; neurotoxicity; patients; urinary bladder neoplasms
- ... Cisplatin is a major chemotherapeutic that continues to have a significant impact in the treatment of more than 50% of all cancers. Since its Food and Drug Administration approval in 1978 for the treatment of advanced ovarian and bladder cancer, this chemotherapeutic has made significant strides and its application has been extended to a large variety of other cancers. However, the vast majority o ...
- Zhou, Qian; You, Chaoqun; Zheng, Cong; Gu, Yawen; Gu, Hongchao; Zhang, Rui; Wu, Hongshuai; Sun, Baiwang
- Life sciences 2018 v.206 pp. 1-9
- DNA; DNA damage; adverse effects; antineoplastic activity; antineoplastic agents; apoptosis; bacteriophages; binding capacity; bioavailability; breast neoplasms; cell cycle checkpoints; cell growth; cell proliferation; circular dichroism spectroscopy; dose response; enzyme inhibition; fluorescence microscopes; growth retardation; humans; interphase; mechanism of action; neoplasm cells; therapeutics; ultraviolet-visible spectroscopy
- ... DNA is considered to be one of the most promising targets for anticancer agents. Acridine analogues have anticancer activity based on DNA binding and topoisomerases inhibition. However, due to the side effects, resistance and low bioavailability, a few have entered into clinical usage and the mechanisms of action are not fully understood. Novel acridine derivatives are needed for effective cancer ...